Introduction {#Sec1}
============

In 1866, Paul Broca was the first to describe a family with a high prevalence of carcinoma of the breast. His wife suffered from early onset of breast cancer and when he made a pedigree of her family, four generations with breast cancer could be identified \[[@CR24]\]. The "Broca" report is the first of many that pointed out that breast cancer can be inherited, passing through from one generation to the other. Family history of breast cancer is now an established risk factor for the development of the disease. In fact, among those variables that have been shown to bear a causal relationship with breast cancer, the highest increased risk, after age, is a positive family history of breast cancer \[[@CR31]\]. With the knowledge of today, only in about 5% of all the breast cancer cases, the disease will occur as part of a hereditary cancer susceptibility syndrome, caused by mutations in high penetrance susceptibility genes. A substantial proportion of hereditary breast cancers, about 16% \[[@CR2], [@CR138]\], can be attributed to germline mutations in either of the *BRCA* (breast cancer 1 and 2) early onset genes. Since the identification of the *BRCA1* and *BRCA2* genes in 1994, several studies have been undertaken to find other high penetrance breast cancer susceptibility genes than *BRCA1* and *BRCA2*, with less spectacular results so far \[[@CR124]\].

Nevertheless, various other genes conferring an increased risk of breast cancer involved in hereditary cancer syndromes have been identified, including *CHEK2*, *PTEN*, *TP53*, *ATM*, *STK11/LKB1*, *CDH1*, *NBS1*, *RAD50*, *BRIP1* and *PALB2*. Some of these genes are involved in multiple cancer syndromes like Li-Fraumeni (*TP53*), Peutz-Jeghers (*STK11/LKB1*) and Cowden syndrome (*PTEN*) \[[@CR49], [@CR69], [@CR94], [@CR125], [@CR161]\]. In Table [1](#Tab1){ref-type="table"}, an overview of the hereditary cancer susceptibility syndrome genes is shown, including their chromosomal location, which syndrome is involved and the clinical features of these syndromes. Table 1Summary of the syndromes associated with hereditary breast cancer, adapted from Tan et al. \[[@CR170]\]Gene involvedCytobandBreast cancer riskSyndromeClinical features*BRCA1*17q21HighHereditary breast cancer and ovarian syndromeBreast cancer, ovarian cancer*BRCA2*13q12.3HighHereditary breast cancer and ovarian syndromeBreast cancer, ovarian cancer, prostate cancer, pancreatic cancer, melanoma*TP53*17p13.1HighLi-Fraumeni syndromeBreast cancer Sarcomas Brain tumors*ATM*11q22.3IntermediateLouis-Bar syndromeLymphoma, cerebellar ataxia, immune deficiency, glioma, medulloblastoma, breast cancer*CDH1*16q22.1IntermediateFamilial diffuse gastric cancer syndromeGastric cancer, lobular breast cancer*PTEN*10q23.31IntermediateCowden syndromeIncreased risk of neoplasms: breast cancer, thyroid cancer, endometrial carcinomas, hamartomatous polyps of the gastrointestinal tractBannayan-Riley-Rivalcaba syndromeBreast cancer, meningioma*STK1*19p13.3IntermediatePeutz-Jeghers syndromeMelanocytic macules of the lips and others multiple gastrointestinal hamartomatous polyps increased risk of neoplasms; breast, testis, pancreas and cervixNBS18q21IntermediateNijmegen breakage syndromeMicrocephaly,growth retardation, immunodeficiency and a marked susceptibility to cancerModerate risk of breast cancer*BRIP/FANCJ*17q22IntermediateFanconi anemiaDevelopmental anomalies affecting the skeleton (absent or abnormal thumbs and radii), kidneys, heart or any other major organ system*PALB2/FANCN*16p12IntermediateAplastic anaemia, acute myeloid leukaemia and squamous cell carcinoma, breast cancer*FANCA*16q24.3Low*FANCE*6p22-p21Low*MSH2*2p22-p21LowLynch cancer family syndromeEndometrial cancer, colorectal cancer, breast cancer, ovarian cancer, genitourinary cancer, sarcomas, glioblastomas and leukaemia (often multiple)*MSH3*5q11-q12Low*MSH6*2p16Low*MLH1*3p21.3Low*PMS1*2q31-q33Low*PMS2*7p22Low

In this paper, we will mainly focus on the hereditary breast cancer syndromes caused by germline mutations in the *BRCA1* and *BRCA2* genes since these have been well studied for their pathological features. Thereafter, we will briefly discuss the rarer hereditary cancer susceptibility syndrome genes mentioned earlier where yet little is known on tumor pathology \[[@CR8], [@CR140], [@CR174]\].

The *BRCA1* and *BRCA2* genes {#Sec2}
-----------------------------

### Discovery {#Sec3}

The *BRCA1* and *BRCA2* genes were discovered in the nineties, starting in 1990 where *BRCA1* was for the first time linked to breast cancer using a large group of early onset breast cancer families and linkage analysis. The *BRCA1* gene was mapped to chromosome 17q21 \[[@CR57]\]. In 1994, the *BRCA1* gene was cloned and truncating mutations were identified in the coding sequence of the *BRCA1* gene in families with multiple cases of breast cancer \[[@CR118]\]. Search for more genes that might be involved in these hereditary susceptibility breast cancer families led in 1995 to the discovery of the *BRCA2* gene. The *BRCA2* gene is located on chromosome 13q12.3, and was discovered also by linking analysis and positional cloning using familial breast cancer pedigrees in successive generations \[[@CR201], [@CR202]\]. At the same time, families with high frequencies of male breast cancer were found to carry the *BRCA2* mutation \[[@CR167]\].

Carriers of the *BRCA1* and *BRCA2* mutations do not only develop breast cancer and ovarian cancer but also bear an increased risk for developing Fallopian tube, colon, melanoma, prostate and pancreatic cancer \[[@CR56], [@CR83], [@CR93], [@CR123], [@CR128], [@CR131], [@CR206]\].

### Structure {#Sec4}

Both *BRCA* genes bear rather complex genomic structures. *BRCA1* is composed of 24 exons and *BRCA2* of 27 exons. They both encode very large proteins: *BRCA1* consists of 1,863 amino acids and *BRCA2* of 3,418 amino acids. In both genes, exon 1 is non-coding and exon 11 is unusually large \[[@CR163], [@CR201], [@CR202]\] (Fig. [1](#Fig1){ref-type="fig"}). *BRCA1* has a highly conserved zinc-binding RING finger domain which is located close to the amino-terminus. RING finger domain proteins are recognized as E3 ligase enzymes that participate in ubiquitination \[[@CR110]\]. Mutations in the RING finger domain inactivate *BRCA* E3 ligase and have an effect on the other tumor suppressor activities of *BRCA1* \[[@CR152]\]. Towards the carboxyl terminus of *BRCA1* two tandem copies of the same motif are found, designated the BRCT domains. These BRCT domains are regions reported to activate transcription when fused to a DNA binding domain \[[@CR27]\]. *BRCA2* contains a number of recognizable motifs, the eight copies of a 20--30 amino acid repeat, termed BRC repeats and the ssDNA binding region. Their function is to bind to RAD51 to regulate DNA repair (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR95], [@CR198]\]. Fig. 1Schematic representation of BRCA1 and BRCA2 functional domains and selected binding partners, partially adapted from Narod et al. \[[@CR124]\]. NLS = Nuclear Localization signal. Some of the proteins interacting with BRCA1 or BRCA2 are marked below the site of interaction

### Function {#Sec5}

Both *BRCA* genes are involved in DNA repair. They form complexes that will activate the repair of double strand breaks (DSBs) and initiate homologous recombination (HR). RAD51 is the key component of this mechanism. Co-localization of BRCA1 and BRCA2 with RAD51 at the site of recombination and DNA damaged induced foci strongly suggest that they are involved in the detection and the repair of DSBs. The roles played by *BRCA1* and *BRCA2* in this process appear to differ. Small ubiquitin-like modifier ligases are essential for localization of BRCA1 at the sites of DNA damage and sumoylated BRCA1 itself, together with BARD1 acts as E3 ligase and further ubiquitinates local proteins \[[@CR47], [@CR121]\]. BRCA1 will associate with RAD51 upon DNA damage and subsequently gets phosphorylated, but the nature of interaction with RAD51 is yet unknown \[[@CR156]\]. BRCA2 has a more direct role through its strict interaction with RAD51 via the BRC repeats \[[@CR200]\]. In addition, RAD51 also interacts with the C-terminal region of *BRCA2*, TR2 \[[@CR119], [@CR160]\]. This part of *BRCA2* is thought to serve a regulatory role in recombinational repair. Phosphorylation of this part of *BRCA2* can provide a dual function, resulting in inhibition or activation during HR \[[@CR36], [@CR40]\]. BRCA2 also has a role in the HR in meiosis via an interaction with RAD51 and DMC1. Given the fact that they have distinct non-overlapping binding sites, it has been suggested that there might well be a BRCA2-RAD51-DMC1 complex. However, more data has to be obtained to confirm this. It does suggest that *BRCA2* not only plays a role in carcinogenesis but in addition contributes to fertility problems in affected carriers \[[@CR176]\].

Cells that are defective for BRCA1 and BRCA2 are hypersensitive for crosslinking agents that will produce double strand breaks like mitomycin c and cisplatin \[[@CR122], [@CR135], [@CR172]\]. Also, ionizing radiation will produce these same breaks and both will be resolved by error-prone repair, such as non homologous end joining \[[@CR204], [@CR205]\]. The levels of expression of BRCA1, BRCA2 and RAD51 increase in cells when they enter the S phase, indicating that they function during or after DNA replication. This means that BRCA1 and BRCA2 function in a common pathway that is responsible for the integrity of the genome and the maintenance of chromosomal stability \[[@CR157]\]. BRCA1 is part of the BRCA1 associated genome surveillance complex (BASC) This complex includes MSH2, MSH6, MLH1, ATM, BLM , the RAD50-MRE11-NBS1 complex and the DNA replication factor C. All the members of this complex have roles in recognition of abnormal or damaged DNA, suggesting that the BASC may serve as a sensor for DNA damage and as a regulator of the post-replication repair process. BRCA1 functions also as a checkpoint control, playing an essential role in cell survival by preventing the propagation of DNA damage through cell cycle progression before DNA repair has taken place \[[@CR197]\]. Taken together, BRCA1 is an integral part of the DNA damage signalling cascade; downstream of ATM and ATR kinases and both downstream and upstream of the checkpoint protein kinases CHEK1 and CHEK2 suggesting that there is a positive feedback loop to increase the magnitude of DNA damage response. In addition, BRCA1 regulates the expression of additional G2M cell cycle checkpoint proteins thereby preventing unscheduled transition into mitosis at multiple levels of regulation. Ubiquitination is the process by which proteins are tagged for degradation by the proteasome. BRCA1 functions with BARD1 in this ubiquitination process \[[@CR144]\]. It has been suggested that BRCA1 plays a role in both transcription coupled repair \[[@CR103]\] and global genome repair \[[@CR59]\]. So, in conclusion, both *BRCA* genes are involved in DNA repair and both function in a common pathway that is responsible for the integrity of the genome and the maintenance of chromosomal stability.

### Mutations {#Sec6}

The Breast Cancer Information Core (BIC) database has recorded 1,639 and 1,853 distinct mutations, polymorphisms and variants in the *BRCA1* and *BRCA2* genes, respectively (data 2010). Mutations appear to be reasonably evenly distributed across the coding sequences, with no obvious "mutation hot spots". Most mutations found in the breast and ovarian cancer families are predicted to truncate the protein product, which will lead to shortened and non-functional BRCA1 and BRCA2 proteins. The most common types of mutations are small frameshift insertions or deletions, non-sense mutation or mutations affecting splice sites, resulting in deletion of complete or partial exons or insertion of intronic sequences. These mutations will cover approximately 70% of the *BRCA1* mutations and 90% of the *BRCA2* mutations in linked families, as estimated by the Breast Cancer Linkage Consortium (BCLC) \[[@CR174]\]. Large-scale rearrangements including insertions, deletions or duplications of more than 500 kb of DNA have also been identified. There have been reports of at least 19 distinct large genomic rearrangements in *BRCA1* and two genomic rearrangements in *BRCA2*, identified using multiplex ligation dependent probe amplification (MLPA). The majority of the rearrangements are deletions of one or more exons \[[@CR73], [@CR120]\]. These mutations can be all classified with reasonable confidence but classification of rare missense changes is still a challenge. According to the BIC database, approximately half of the unique *BRCA1* and *BRCA2* variants detected (excluding common polymorphisms) are missense variants of unknown pathogenic potential, termed "unclassified variants". Note of concern here is that the BIC database did not take into account the frequency in which these variants were found in the population undergoing testing. Furthermore, the clinical relevance of only a few unclassified variants has been established. For the others, the subtle alteration might not alter the function of the protein and there might also be insufficient information about the family history to classify these unclassified variants as cancer predisposing changes. However, these alterations can provide indications to do further functional and family studies \[[@CR30], [@CR104]\]. It has been stated that a new approach is needed to improve the association between these unclassified variants and breast cancer risk, and that using histopathology data of tumors from carries of an unclassified variant could be helpful \[[@CR165]\].

Loss of heterozygosity (LOH) of the wildtype allele has been robustly demonstrated for *BRCA* linked breast cancer. Although some of the studies mentioning a role of LOH in approximately 80% of the cases included in the studies, for the rest of the cases LOH affecting the *BRCA* gene could not be detected \[[@CR32], [@CR33], [@CR54], [@CR127]\]. This might be caused by the practical and conceptual problems associated with LOH studies \[[@CR178]\]. Furthermore, LOH of the wild type allele is not required for *BRCA* linked breast tumorigenesis and when it occurs it is probably a late event \[[@CR92]\]. Another consideration is whether a second somatic mutation or methylation dependent silencing affecting the wild type allele accounts for these findings. However, no evidence of a second somatic mutation in *BRCA* linked breast cancer has been found so far. *BRCA* promoter hypermethylation as a gene silencing mechanism has been reported in 11%--30% and 42%--51% of sporadic breast cancer and non-*BRCA1*/*BRCA2* related hereditary breast cancers, respectively \[[@CR19], [@CR42], [@CR76], [@CR171]\]. *BRCA1* and *BRCA2* related breast tumours only rarely showed *BRCA* promoter hypermethylation \[[@CR37], [@CR41], [@CR169], [@CR171]\]

### Population specific occurrence {#Sec7}

The majority of all the mutation described above are found throughout the population. However, certain mutations in *BRCA1* and *BRCA2* have been observed to be common in specific populations. Such founder mutations in *BRCA1* and *BRCA2* have been described in French Canadian \[[@CR162]\], Swedes \[[@CR86]\], Icelandic women \[[@CR175]\], Norwegians \[[@CR7]\], Finns \[[@CR80]\], Dutch women \[[@CR136], [@CR139]\], Russians \[[@CR50]\], Japanese women \[[@CR82]\] and African Americans \[[@CR48]\]. Three founder mutations are very commonly found in the Ashkenazi Jewish population, the 185delAG \[[@CR129], [@CR168]\] and 5382insC in *BRCA1* and 6147delT in *BRCA2* \[[@CR9], [@CR126]\]. The 185delAG is prevalent in 1% of all Ashkenazi Jews but has also been reported in other Jewish groups \[[@CR16]\]. The 5382insC mutation found in 0.1% of the Ashkenazi Jews is described to occur more widespread, being common in Poland, Russia, and other parts of Eastern Europe and occurring in most European populations. In Ashkenazi Jewish women with breast cancer, the 185delAG mutation in *BRCA1* is found in 20% \[[@CR130]\]. The 6147delT mutation in *BRCA2* is found to be present in 8% of the Ashkenazi Jews with breast cancer \[[@CR126], [@CR179]\]. In Iceland, a single *BRCA2* mutation 999del5 has been identified and is present in the majority of familial breast cancer cases in this population \[[@CR55], [@CR175]\].

Pathology of *BRCA1* related breast cancer {#Sec8}
------------------------------------------

### Histology {#Sec9}

The histology of *BRCA1* associated breast cancers differs from the histopathological features of sporadic breast cancers in various aspects. The majority of the *BRCA1* associated tumors are invasive ductal adenocarcinomas (74%). However, compared to sporadic breast cancer, a significantly higher frequency of the *BRCA1* associated tumors are classified as medullary like carcinomas, 2% versus 13% respectively \[[@CR1], [@CR99]\]. The remaining histological types of breast cancer occur about equally in *BRCA1* mutation associated tumors and in sporadic breast cancer \[[@CR1]\]. With regard to other histopathological characteristics it is observed that *BRCA1* tumors are more frequently poorly differentiated (grade 3), have a high mitotic count and show an high frequency of necrotic areas \[[@CR186]\]. Tubule formation is decreased, but a higher degree of pleimorphism is observed, all aspects pointing at a more aggressive phenotype \[[@CR10], [@CR75], [@CR99], [@CR112]\]. In addition, tumors are often well demarcated and show a remarkable degree of lymphoplasmocytic infiltration, and a high frequency of lymphovascular invasion \[[@CR66]\].

When considering the age of onset of these *BRCA1* mutation carriers, less than 50 years of age compared to age above 50 years, significant differences in grade (higher) and in percentage of medullary type (more cases), of breast cancer are seen in the younger population \[[@CR38]\]. With regard to pre-invasive breast lesions, it has initially been reported that ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are seen less frequently in *BRCA1* mutation carriers, being 41% and 2% respectively versus 56% and 6% in non-carriers. These concerned however pre-invasive lesions in cases where invasive breast cancer was seen \[[@CR1], [@CR13]\]. Studies investigating the occurrence of premalignant lesions in prophylactic mastectomies of *BRCA1* mutation carriers usually showed more frequent occurrence of premalignant lesions. These premalignant lesions concern DCIS \[[@CR79], [@CR84], [@CR90]\], LCIS \[[@CR79]\], atypical ductal (ADH) \[[@CR71], [@CR79], [@CR84], [@CR90]\] and atypical lobular hyperplasia (ALH) \[[@CR71], [@CR79], [@CR84], [@CR90]\], usual ductal hyperplasia \[[@CR71]\], columnar cell lesions \[[@CR90]\] and fibroadenoma \[[@CR71], [@CR97]\]. Interestingly, the remarkable lymphocytoplasmic infiltrate described in invasive *BRCA1* related cancers has also been described in DCIS lesions and even the normal breast shows T-cell lobulitis \[[@CR72]\].

### Immunophenotype {#Sec10}

The immunophenotype of the *BRCA1* mutation related breast cancers (Table [2](#Tab2){ref-type="table"}) is first of all characterized by a low expression of the estrogen receptor alpha (ERα). In 1997 the first reports about the low expression of ERα in *BRCA1* tumors compared to sporadic tumors were described. Subsequent reports confirmed this observation and in addition described a significant relationship between low ERα on the one hand and high grade \[[@CR11], [@CR38], [@CR44], [@CR87], [@CR88], [@CR101], [@CR111], [@CR134]\] and an earlier age of onset \[[@CR38], [@CR44], [@CR192]\] on the other. In contrast, overexpression of estrogen receptor beta (ERβ) is seen in breast cancers of *BRCA1* mutation carriers \[[@CR109]\]. Similar low expression of the progesterone receptor (PR) has been reported \[[@CR11], [@CR38], [@CR101], [@CR111], [@CR134]\].

Overall, the expression of the human epidermal growth receptor 2 (HER-2/*neu*) is low in *BRCA1* related breast cancers when compared with controls \[[@CR11], [@CR75], [@CR101]\]. Furthermore, HER-2/*neu* amplifications among *BRCA1* tumors have only rarely been reported. One explanation could be that in the background of a *BRCA1* germline mutation, HER-2/*neu* is lost during loss of heterozygosity (LOH) at the BRCA1 locus since HER-2/*neu* is localized close to *BRCA1* on chromosome 17 \[[@CR3], [@CR53], [@CR134]\].

In contrast to HER-2/neu, overexpression of the epidermal growth factor receptor (EGFR) has been strongly associated with *BRCA1* associated breast cancers \[[@CR45], [@CR100], [@CR187], [@CR188], [@CR191]\].

*BRCA1* related breast cancers often lack cyclin D1 (CCND1) expression. Also the expression of p27^Kip1^ is very low in *BRCA1* related breast cancers and this is seen together with high levels of cyclin E \[[@CR44]\]. Mutations in the *TP53* gene are seen in 30%--77% of *BRCA1* tumors whereas they are only present in about 20% of sporadic controls. As a consequence, accumulation of p53 is often seen in *BRCA1* related breast cancer. Furthermore, the distribution of the *TP53* mutations might be influenced by the *BRCA1* and *BRCA2* genes \[[@CR11], [@CR34], [@CR52], [@CR74], [@CR141]\].

Evaluating the expression of several basal markers in *BRCA1* related breast cancers it was observed that most of these tumors are positive for cytokeratins CK5/CK6 and CK14 \[[@CR45], [@CR100]\], caveolin 1\[[@CR143]\], vimentin, laminin \[[@CR151]\] and p-cadherin \[[@CR12]\].

Expression of the apoptosis related proteins BAX and BCL2 in *BRCA1* related breast cancers is lower compared to sporadic breast cancers is reported \[[@CR46], [@CR133], [@CR134]\]. In contrast, high levels of active caspase 3 were observed in *BRCA1* tumors \[[@CR133]\]. Hypoxia inducible factor-1α (HIF-1α) is the key regulator of the hypoxia response. HIF-1α is overexpressed during sporadic breast carcinogenesis \[[@CR22]\] and correlated with poor prognosis \[[@CR21], [@CR195]\]. It appears to be involved in *BRCA1* related breast cancers, where HIF-1α is overexpressed in most of these tumors \[[@CR186]\]. Expression of the stem cell marker ALDH1 appeared to be higher in *BRCA1* related breast cancers compared to sporadic cancers \[[@CR64]\] , indicating that these cancers bear an increased cancer stem cell compartment. Intrestingly, there was no difference between normal breast tissue of *BRCA1* mutation carriers and controls \[[@CR65]\]

Altogether, this immunophenotype indicates that *BRCA1* related invasive breast cancer largely shows the immunophenotype of progenitor cells of the breast, indicating that they initially may (in contrast to *BRCA2* related cancers, see below) derive from these cells. While the immunophenotype of invasive *BRCA1* related cancers has been well studied little is yet known on the immunophenotype of pre-invasive lesions from the *BRCA1* carcinogenetic spectrum. We recently showed that the immunophenotype of DCIS in *BRCA1* carriers is similar to that of their accompanying invasive cancers \[[@CR190]\].

### Genetic profile {#Sec11}

Gene expression profile analysis has provided a tool to distinguish distinct subtypes of breast cancers \[[@CR137], [@CR164]\]. Based on these data *BRCA1* associated breast cancers are classified as basal. The gene expression profile of *BRCA1* associated tumors involves genes that were found to have functions in proliferation, angiogenesis, cell motility, cell adhesion, transcription and DNA repair. As mentioned above, *BRCA1* related breast tumors express basal markers like CK 5/6, CK14, EGFR, P-cadherin and caveolin 1, vimentin and laminin, thereby confirming the basal subtype as established by immunohistochemistry \[[@CR45], [@CR100], [@CR151]\]. These data further underline that carcinogenesis in *BRCA1* germline mutation carriers very often occurs within the "basal" progression route.

Promotor hypermethylation of tumor suppressor genes has been shown to be somewhat less abundant in *BRCA1* germline mutation related breast cancers \[[@CR169]\], although it is still clearly higher than in normal tissue.

As to copy number changes, a different pattern of chromosomal copy-number gains and losses compared to sporadic controls has been found. Copy number changes frequently occurring in *BRCA1* related breast cancers are gains of 3q, 7p, 8q 10p, 12p, 16p and 17q and loss of 2q, 3p, 4p, 4q, 5q, 12q, 16p and 18q. This only partly overlaps with copy number changes found in sporadic and *BRCA2* germline mutation related breast cancers, see Table [3](#Tab3){ref-type="table"} \[[@CR177], [@CR185], [@CR199]\]. Table 2Chromosomal loci showing significant differences in frequency of gain or loss by array comparative genomic hybridization between BRCA1 and BRCA2 related and sporadic breast cancers \[[@CR185]\]LocusFrequency*p*-valueBRCA1BRCA2SporadicBRCA1 vs sporadicBRCA2 vs sporadicBRCA1 vs BRCA2Gains1cen-p138968870.0543pter-p22331600.0063q13-q276756130.0000.0738p12-cent1116470.0129p331630.0789q22-q3403230.01310pter-p12502070.00010p12-q2136430.08913q325800.05916p1724570.01918p281630.025Losses5cent-q237240270.02514q1-q2398100.048

### Prognosis {#Sec12}

In *BRCA1* associated tumors, a lower rate of bone metastases and a higher frequency of lung and brain metastases have been described \[[@CR96]\]. Investigating overall survival in *BRCA1* associated breast cancer versus age matched sporadic breast cancer patients have yielded contradictive results with some studies describing a worse survival and others a similar survival rate \[[@CR23], [@CR58], [@CR107], [@CR147], [@CR150], [@CR194]\].

Pathology of *BRCA2* related breast cancer {#Sec13}
------------------------------------------

### Histology {#Sec14}

Similar to *BRCA1* related breast cancers, the most common histological type in *BRCA2* tumors is invasive ductal carcinoma (76%) \[[@CR1]\]. Reports of a higher incidence of tumors belonging to invasive (pleiomorphic) lobular, tubular and cribiform carcinomas in *BRCA2* related breast cancers compared to sporadic breast cancer have been published \[[@CR4], [@CR10], [@CR14], [@CR99], [@CR112], [@CR113]\]. *BRCA2* tumors are more frequently moderately or poorly differentiated carcinomas (grade 2 and 3) \[[@CR4], [@CR99], [@CR111], [@CR134]\] due to less tubule formation \[[@CR1]\] more nuclear pleiomorphism and higher mitotic rates compared to controls \[[@CR4], [@CR14]\]. *BRCA2* related breast cancers have, as *BRCA1* related cancers, a higher proportion of continuous pushing margins in comparison to sporadic breast cancers \[[@CR14], [@CR99]\]. With regard to pre-invasive breast lesions it has been described that DCIS and LCIS in *BRCA2* mutation carriers occur in the same frequency, 52% and 3% respectively compared to 56% and 6% in control individuals \[[@CR1], [@CR13], [@CR78]\]. The occurrence of premalignant lesions in prophylactic mastectomies of *BRCA2* mutation carriers show different results, similar to what has been observed in *BRCA1* mutation carriers, ranging from no differences to the more frequent occurrence of premalignant lesions in prophylactic mastectomies of *BRCA2* mutation carriers like DCIS \[[@CR79], [@CR90]\], LCIS \[[@CR79], [@CR84]\], ADH \[[@CR71], [@CR79], [@CR84], [@CR90]\], ALH \[[@CR71], [@CR79], [@CR84], [@CR90]\] and columnar cell lesions \[[@CR90]\]. Interestingly, the remarkable lymphocytoplasmic infiltrate described in invasive *BRCA2*, and in *BRCA1* as mentioned before, related cancers has also been described in DCIS lesions, and even the normal breast shows T-cell lobulitis \[[@CR72]\].

### Immunophenotype {#Sec15}

The immunophenotype of *BRCA2* related breast cancers is similar to the immunophenotype of sporadic breast cancers (Table [2](#Tab2){ref-type="table"}). As a consequence, most *BRCA2* tumors show a different immunophenotype compared to *BRCA1* related breast tumors as discussed above. *BRCA2* cancers show more frequently expression of ERα and PR \[[@CR4], [@CR10], [@CR14], [@CR38], [@CR45]\]. Furthermore, these ER positive *BRCA2* related breast cancers decrease in frequency with increasing age \[[@CR44]\]. In *BRCA2* related breast cancer different studies report no or low expression of HER-2/*neu* compared to sporadic breast cancer and only in rare cases a HER-2/*neu* amplification was found \[[@CR14], [@CR101], [@CR132], [@CR134]\]. Furthermore, a more recent study described that *BRCA2* related breast cancers are characterized by a higher expression of fibroblast growth factor 1 (FGF1) and fibroblast growth factor receptor 2 (FGFR2) compared to *BRCA1* related breast cancers. This could help to distinguish *BRCA2* related breast cancers from other breast cancers \[[@CR15]\]. The *BRCA2* related breast cancers usually express only "luminal" cytokeratins like CK8 and CK18 and not CK5/6 and CK14 \[[@CR133]\]. In *BRCA2* related breast cancers no expression of caveolin1 has been described in contrast to the expression of caveolin in *BRCA1* related tumors \[[@CR143]\]. No differences or even lower levels of the incidence of p53 have been reported for *BRCA2* related breast cancers in comparison with *BRCA1* related breast cancers \[[@CR133]\]. Higher expression of cyclin D1, BAX and BCL2 in *BRCA2* related breast cancers compared to *BRCA1* and non-*BRCA* carriers have been described \[[@CR133], [@CR134]\]. However, anecdotic data suggest that EGFR expression is high in *BRCA2* related cancers \[[@CR188]\]. While *BRCA1* related cancers have been described to be frequently positive for P-cadherin, vimentin and HIF-1α, no such data are yet available for *BRCA2* related cancers. No data on ALDH1 expression in *BRCA2* related cancers are available.

While the immunophenotype of invasive *BRCA2* related cancers has been well studied, little is yet known on the immunophenotype of pre-invasive lesions from the *BRCA2* carcinogenetic spectrum. We recently showed that the immunophenotype of DCIS in *BRCA2* carriers is similar to that of their accompanying invasive cancers \[[@CR190]\].

In conclusion, most of the *BRCA2* related breast cancers are of the so called luminal type with overexpression of ER, PR, CK8 and CK18. This is clearly different from the observations in *BRCA1* related breast cancers \[[@CR101], [@CR134]\], pointing to a different origin from the luminal cells of the breast rather than the progenitor cells as in *BRCA1* related breast cancer.

### Genetic profile {#Sec16}

In a recent study using gene expression analysis to distinguish *BRCA2* associated tumors, discriminating genes were those related to transcription, signal transduction, cell proliferation, cell adhesion and extracellular matrix remodelling. In this study, a relative high expression of FGF1 and FGFR2 was observed and this was confirmed by immunohistochemistry as stated above \[[@CR15], [@CR61], [@CR184], [@CR199]\]. When using the gene expression profile mentioned before, most of the *BRCA2* related breast cancers were classified as luminal \[[@CR137], [@CR164]\]. Looking more specifically at the molecular genetics, *BRCA2* related breast cancers show patterns of chromosomal copy-number gains and losses that are not found in sporadic controls. Copy number changes more frequently occurring in *BRCA2* related breast cancers are gains of 8q, 17q22-q24 and 20q13 and loss of 8p, 6q, 11q and 13q \[[@CR177], [@CR185]\], see Table [3](#Tab3){ref-type="table"}.

### Prognosis {#Sec17}

In women with *BRCA2* associated breast cancer, bone and soft tissue metastases are observed more frequently likely associated with their more frequent ER positivity \[[@CR96]\]. As is the case in *BRCA1* patients, for *BRCA2* patients conflicting data with regard to outcome have been presented \[[@CR23], [@CR58], [@CR107], [@CR147], [@CR150], [@CR194]\].

Other hereditary breast cancer genes {#Sec18}
------------------------------------

### TP53 {#Sec19}

*TP53* (tumor protein p53) is a tumor suppressor gene located on chromosome 17p13.1 encoding a nuclear phosphoprotein (p53). *TP53* acts as a transcription factor involved in the control of cell cycle progression, repair of DNA damage, genomic stability, and apoptosis \[[@CR196]\]. *TP53* is constitutionally mutated in the Li-Fraumeni syndrome, an autosomal dominant predisposition to breast cancer and other forms of cancer (see Table [1](#Tab1){ref-type="table"}). Most mutations are point mutations leading to proteins defective for sequence-specific DNA binding and activation of p53 responsive genes \[[@CR49], [@CR94], [@CR161]\]. The *TP53* gene is more commonly altered in *BRCA1* (56%--100%) and *BRCA2* (29%) related breast cancer in comparison with non-*BRCA* related breast \[[@CR29], [@CR74]\]. In *BRCA1* or *BRCA2* deficient cells changes were seen at *TP53* codons that are not the mutation hotspots. Structural modelling showed that most of these p53 non-hot spot aminoacids are distributed in a region of the protein on the opposite side of the p53 DNA-binding surface in these *BRCA1* or *BRCA2* deficient cells \[[@CR52]\]. Breast cancers with these *TP53* non-hot spot mutations were associated with a significantly better prognosis when compared with *TP53* mutations in conserved or structural domains \[[@CR6]\]. Preliminary data suggest that *BRCA1* or *BRCA2* mutations influence the distribution of the *TP53* mutations and the way of carcinogenesis, but additional studies must be performed to support this \[[@CR52]\]. Table 3Chromosomal loci showing significant differences in frequency of gain or loss by array comparative genomic hybridization between BRCA1 and BRCA2 related and sporadic breast cancers \[[@CR185]\]LocusFrequency*p*-valueBRCA1BRCA2SporadicBRCA1 vs sporadicBRCA2 vs sporadicBRCA1 vs BRCA2Gains1cen-p138968870.0543pter-p22331600.0063q13-q276756130.0000.0738p12-cent1116470.0129p331630.0789q22-q3403230.01310pter-p12502070.00010p12-q2136430.08913q325800.05916p1724570.01918p281630.025Losses5cent-q237240270.02514q1-q2398100.048

### CHEK2 {#Sec20}

The *CHEK2* (checkpoint kinase 2) gene is located on chromosome 22q12.1 and encodes a cell cycle checkpoint kinase which is a key mediator in DNA damage response \[[@CR115], [@CR203]\]. Mutations in *CHEK2* were originally thought to result in the Li-Fraumeni syndrome or in a Li-Fraumeni-like syndrome (mentioned above and described in Table [1](#Tab1){ref-type="table"}), since the first *CHEK2* mutations were found in these Li-Fraumeni families \[[@CR18]\]. More recent studies question this association, following the identification of the 1000delC and 1157T *CHEK2* germline variants among breast cancer patients that otherwise show no signs of Li-Fraumeni like features \[[@CR5], [@CR183]\]. The *CHEK2* gene has been proposed to be a low penetrance breast cancer susceptibility gene. The 1000delC variant results in an approximately two fold risk of breast cancer in women and a tenfold risk in men. In these cases, there is no mention of co-existence of *BRCA1* and *BRCA2* mutations \[[@CR117], [@CR182]\]. So far, beside the 1000delC and 1157T mutations, no additional *CHEK2* mutations have been found \[[@CR155]\].

### ATM {#Sec21}

The *ATM* (ataxia teleangiectasia mutated) gene is located on chromosome 11q22.3 and encodes a checkpoint kinase that plays a role in DNA repair. Biallelic mutations in this gene are linked to the rare human autosomal recessive disorder called ataxia teleangiectasia (AT) \[[@CR153]\], causing a variety of somatic disorders as described in Table [1](#Tab1){ref-type="table"}. A heterozygous mutation of *ATM* does not lead to the AT phenotype but carriers have a two to five fold risk of breast cancer \[[@CR148], [@CR173]\] (Table [1](#Tab1){ref-type="table"}).

### CDH1 {#Sec22}

*CDH1* (Cadherin 1, E-cadherin) is a gene located on chromosome 16q22.1 encoding E-cadherin, a calcium dependent cell adhesion glycoprotein, which is important for cell-to-cell adhesion \[[@CR17]\]. Familial diffuse gastric cancer, an autosomal dominant cancer syndrome is caused by mutations in the *CDH1* gene and affected women are predisposed to lobular breast cancer. Patient with a familial diffuse gastric cancer have a risk of about 50% of getting breast cancer \[[@CR91], [@CR154]\] (Table [1](#Tab1){ref-type="table"}).

### PTEN {#Sec23}

*PTEN* (phosphatase and tensin homolog), is a tumor suppressor gene located on chromosome 10q23.3. *PTEN* encodes for the protein phosphatidylinositol phosphate phosphatase and has multiple and as yet incompletely understood roles in cellular regulation\[[@CR106], [@CR166]\]. Germline mutations in *PTEN* can lead to a rare autosomal dominant inherited cancer syndrome, Cowden disease, characterized by a high risk of breast-, thyroid- and endometrial carcinomas and hamartomas \[[@CR125]\]. Mutations in *PTEN* also cause the related syndrome, Bannayan-Riley-Rivalcaba syndrome \[[@CR114]\], see for more details Table [1](#Tab1){ref-type="table"}.

### STK11 {#Sec24}

*STK11 (LKB1)* (Serine/theronine kinase 11) is a gene located on chromosome 19p13.3 that encodes a serine/threonine kinase and functions mainly through inhibition of the mTOR pathway. *STK11* is mutated in the autosomal dominant condition Peutz-Jeghers syndrome, characterized by perioral pigmentation and hamartomatous polyposis \[[@CR69]\]. Patients with this syndrome have a 30%--50% risk of developing breast cancer \[[@CR51], [@CR60], [@CR108]\] (Table [1](#Tab1){ref-type="table"}).

### NBS1 {#Sec25}

*NBS1* is a gene located on chromosome 8q21 and involved in the Nijmegen breakage syndrome, a chromosome instability syndrome. Proteins of the gene *NSB* together with proteins of the genes *RAD50* and *MRE11*, form the so called MRN complex. The MRN complex is involved in the recognition and repair of DNA double strand breaks \[[@CR102]\]. The estimated prevalence of the most common mutation is very low and the breast cancer risk conferred by a *NBS1* mutation is estimated to be low \[[@CR20]\].

### FANCONI {#Sec26}

A rare recessive repair defect disorder called Fanconi anaemia (FA) is linked to a number of genes, in total 12 so far, that, together with BRCA1, are involved in homologous recombination DNA repair mechanisms \[[@CR35], [@CR85], [@CR193]\]. Mutations in *FANCJ* (=*BRIP1*) and *FANCN* (= *PALB2*) are associated with a two fold increased risk of breast cancer \[[@CR145], [@CR158]\]. The remaining ten FA genes may likewise be involved in the carcinogenesis of breast cancer but their role has not been elucidated yet. It has been suggested that the remaining FA genes are inactivated through epigenetic/transcriptional mechanisms. For example, the FANCD2 protein is down regulated in sporadic and in hereditary breast carcinomas \[[@CR189]\].

### Mismatch repair {#Sec27}

Postreplication mismatch repair (MMR) is a critical mechanism for maintaining microsatellite stability through the correction of base substitution mismatches and insertion/deletion events. The *mismatch repair genes (MMR), MLH1, MSH2* and *MSH6,* play a role in hereditary non-polyposis colorectal cancer, the Lynch-syndrome. In a few of these families, breast cancer is part of this syndrome, which seems to be related to the absence of the MLH1and MSH2 proteins \[[@CR159]\]. Furthermore, a causative role of MSH6 in the occurrence of breast cancer has been suggested but only one case has been reported so far \[[@CR70]\].

Together with *BRCA1* and *BRCA2*, the above described genes account for most, but not all, hereditary breast cancers (Fig. [2](#Fig2){ref-type="fig"}). Obviously, the search for other genes involved in hereditary breast cancer is still continuing \[[@CR149]\]. Fig. 2Affected genes in hereditary breast cancer

Pathology of *non-BRCA1* or *non-BRCA2* related breast cancers {#Sec28}
--------------------------------------------------------------

Phenotypic characteristics of cancers developing in patients with a strong family history without a *BRCA1* or *BRCA2* germline mutation are various. These breast cancers develop as a consequence of mutations in different moderate to low penetrance genes, like the genes mentioned earlier (see Table [1](#Tab1){ref-type="table"}), or in genes yet to be discovered. It has been established that these tumors have even a lower grade compared to sporadic breast cancers. Furthermore, the immunophenotype is more or less the same as shown in sporadic breast disease \[[@CR76], [@CR98]\]. One study describing a gene expression profile of non-*BRCA* related breast cancer was able to classify these tumors into two homogenous subsets, ribosomal genes were more represented in one of these groups compared to the other based on a 60 gene set. Additional experiments should be done on these non-*BRCA* related tumors to further describe their molecular characteristics \[[@CR62]\].

### CHEK2 {#Sec29}

Morphologic and immunophenotypic studies of breast cancer in patients with a *CHEK2* mutation has yielded conflicting results, largely due to the limited cases of breast cancers that have been found being related to this mutation. Studies on ER and PR expression have reported contradictory results, ranging from similar to overexpression of ER and PR. Breast cancer in patients with a U157T mutation has been associated with an increased incidence of lobular carcinomas as has been described earlier \[[@CR77], [@CR81]\].

### PALB2 {#Sec30}

A recent study describes for the first time some tumors characteristics of *PALB2*, 1592delT, mutation carriers. Most of these breast tumors exhibited a phenotype of high grade mostly of ductal type and ER, PR and HER-2/*neu* receptor negativity. They were mostly CK5/6, CK14 and CK17 negative, showed high expression of Ki67 and low expression of Cyclin D1 as compared with other familial and sporadic patients \[[@CR67]\]

In conclusion, the pathology of hereditary breast cancers not related to a *BRCA1* or *BRCA2* mutation has not been studied extensively and so far does not seem very specific.

Clinical relevance {#Sec31}
==================

Surgical options for surveillance include prophylactic bilateral mastectomy and prophylactic bilateral salpingo-oophorectomy (BSO) \[[@CR146]\]. Prophylactic bilateral mastectomy reduces the risk of breast cancer by almost 100% in mutation carriers \[[@CR63], [@CR116]\]. In view of the additional high lifetime risk of ovarian cancer, especially in *BRCA1* mutation carriers, these women are strongly advised to undergo BSO including the removal of the Fallopian tubes at the completion of childbearing \[[@CR89], [@CR105], [@CR142]\].

Preliminary results from one study suggests that the use of hormone therapy in postmenopausal women with a *BRCA1* mutation was associated with a decreased risk of breast cancer. It is important to confirm this in a larger study including different populations and a longer study period \[[@CR39]\].

The association of negativity ER/PR/HER-2/*neu* status classifies many of *BRCA1* related cancers in the "triple negative" category, which is clinically under scrutiny as these cancers may require an alternate chemotherapeutic approach. Due to the important role of the *BRCA* genes in DNA repair it could be expected that DNA cross linking agents, like cisplatin and mitomycine-c, would have an effect especially in those diseases that occur as a consequence of mutated and therefore dysfunctional *BRCA1* and *BRCA2* genes \[[@CR181]\]. Higher tumor responses to platinum based chemotherapy have indeed been observed in patients with *BRCA1* mutated ovarian cancers when compared with the effects observed in non hereditary ovarian cancer \[[@CR26], [@CR28]\].

A potentially new strategy that has emerged for treatment of *BRCA1* and *BRCA2* related tumors is the use of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. *BRCA1* and *BRCA2* are both involved in DNA double strand break repair, as mentioned before. PARP1 is involved in base excision repair, a key pathway in the repair of DNA single strand break. The absence of PARP leads to spontaneous single strand breaks which collapse replication forks into double strand breaks, triggering homologous recombination for repair. However, with the loss of functional *BRCA1* or *BRCA2*, cells will be sensitized to inhibit PARP activity, apparently leading to the persistence of the DNA lesions which are usually repaired by homologous recombination. When both pathways are defect this will result in chromosomal instability, cell cycle arrest and finally apoptosis. Cell survival assays show that cell lines lacking wildtype *BRCA1* or *BRCA2* were extremely sensitive to PARP inhibitors compared to heterozygous mutant or the wildtype cells \[[@CR43]\]. Similar results were obtained using non embryonic cells deficient for *BRCA2*. These results suggest the potential use of PARP inhibitors in the treatment of *BRCA1* and *BRCA2* related breast cancer. This is presently evaluated in various clinical trials in *BRCA* carriers suffering from breast and/or ovarian cancer \[[@CR25], [@CR43], [@CR68], [@CR180]\].

Conclusions {#Sec32}
===========

*BRCA1* related breast cancers are very well characterized by morphological, immunohistochemical and molecular features that clearly help to differentiate them from sporadic tumors and identify high risk patients for mutation testing. *BRCA2* related breast cancers on the other hand, offer yet only a few morphological, immunohistochemical or molecular features to separate them from sporadic controls.

Finally, although numbers studied so far are small, breast cancers caused by other breast cancer susceptibility genes do not, as in *BRCA2* related disease, seem to differ significantly from sporadic breast cancers.

More studies should be performed on morphological, immunohistochemical and molecular characterization of *BRCA2* related breast cancers, breast cancers caused by unclassified variants of *BRCA1* and *BRCA2*, and breast cancers caused by other breast cancer susceptibility genes to gain insight into the development of these breast cancers, and to subsequently be able to offer clues for diagnosis and new therapeutic approaches.
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